Drug
Idp 122 Lotion
Idp 122 Lotion: highest development phase Post-Market, developed by Bausch Health. 3 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Bausch Health
Trials
| Drug | Phase | Indication |
|---|---|---|
| IDP-122 Lotion NCT03987763 | Post-Market | Psoriasis |
| IDP-122 Lotion NCT02514577 | Phase 3 | Plaque Psoriasis |
| IDP-122 Lotion NCT02515097 | Phase 3 | Plaque Psoriasis |
Latest
Follow Idp 122 Lotion on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.